Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone Initiation Registry Randomized Interventional Trial in HFpEF
2016-002019-16Phase 3Active
- Sponsor
- Uppsala Clinical Research Center
- Start
- Jul 2016
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in heart failure with preserved ejection fraction (HFpEF) comparing Spironolactone or eplerenone plus standard of care with Standard of care alone (2 arms). Primary endpoint: Time to cardiovascular death or first heart failure hospitalization. Started Jul 2016; status: active.
02
Drugs
spironolactoneeplerenone
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on 2016-002019-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002019-16.